Which has preferable valuation and earnings, ADAG or OLMA?

Adagene has higher revenue and earnings than Olema Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 29.28 -$17.61M N/A N/A Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A

Is ADAG or OLMA more profitable?

Adagene's return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Olema Pharmaceuticals N/A -48.26% -43.04%

Does the media favor ADAG or OLMA?

In the previous week, Adagene and Adagene both had 10 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Adagene's score of 0.31 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Olema Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ADAG or ANNX?

Adagene has higher revenue and earnings than Annexon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 29.28 -$17.61M N/A N/A Annexon N/A N/A -$206.69M -$1.16 N/A

Is ADAG or ANNX more profitable?

Adagene's return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Annexon N/A -106.15% -79.82%

Does the media favor ADAG or ANNX?

In the previous week, Adagene had 5 more articles in the media than Annexon. MarketBeat recorded 10 mentions for Adagene and 5 mentions for Annexon. Annexon's average media sentiment score of 1.07 beat Adagene's score of 0.31 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ADAG or RIGL?

Rigel Pharmaceuticals has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 29.28 -$17.61M N/A N/A Rigel Pharmaceuticals $294.28M 2.97 $367.02M $16.32 2.89

Does the media prefer ADAG or RIGL?

In the previous week, Adagene had 8 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 10 mentions for Adagene and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.94 beat Adagene's score of 0.31 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ADAG or CLYM?

Adagene has higher revenue and earnings than Climb Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 29.28 -$17.61M N/A N/A Climb Bio N/A N/A -$59.85M -$0.83 N/A

Is ADAG or CLYM more profitable?

Adagene's return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Climb Bio N/A -31.79% -30.79%

Does the media prefer ADAG or CLYM?

In the previous week, Adagene and Adagene both had 10 articles in the media. Climb Bio's average media sentiment score of 0.90 beat Adagene's score of 0.31 indicating that Climb Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Climb Bio 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ADAG or SLN?

Adagene has higher revenue and earnings than Silence Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 29.28 -$17.61M N/A N/A Silence Therapeutics $560K 1,399.88 -$88.61M -$1.28 N/A

Adagene (ADAG) Competitors

$3.40 +0.09 (+2.72%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.40 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Compare

ADAG vs. OLMA, ANNX, RIGL, CLYM, and SLN

Should you buy Adagene stock or one of its competitors? Adagene's main competitors and comparable companies include Olema Pharmaceuticals (OLMA), Annexon (ANNX), Rigel Pharmaceuticals (RIGL), Climb Bio (CLYM), and Silence Therapeutics (SLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adagene compare to Olema Pharmaceuticals?

Adagene (NASDAQ:ADAG) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

9.5% of Adagene shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Adagene has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

In the previous week, Adagene and Adagene both had 10 articles in the media. Olema Pharmaceuticals' average media sentiment score of 0.96 beat Adagene's score of 0.31 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Olema Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene's return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

Adagene has higher revenue and earnings than Olema Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	29.28	-$17.61M	N/A	N/A
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Adagene presently has a consensus target price of $9.50, indicating a potential upside of 179.41%. Olema Pharmaceuticals has a consensus target price of $42.40, indicating a potential upside of 314.87%. Given Olema Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Olema Pharmaceuticals is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Adagene and Olema Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Adagene compare to Annexon?

Adagene (NASDAQ:ADAG) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

9.5% of Adagene shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Adagene had 5 more articles in the media than Annexon. MarketBeat recorded 10 mentions for Adagene and 5 mentions for Annexon. Annexon's average media sentiment score of 1.07 beat Adagene's score of 0.31 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene's return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Annexon	N/A	-106.15%	-79.82%

Adagene has higher revenue and earnings than Annexon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	29.28	-$17.61M	N/A	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Adagene has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Annexon has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Adagene currently has a consensus target price of $9.50, indicating a potential upside of 179.41%. Annexon has a consensus target price of $15.14, indicating a potential upside of 284.34%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Adagene beats Annexon on 9 of the 13 factors compared between the two stocks.

How does Adagene compare to Rigel Pharmaceuticals?

Adagene (NASDAQ:ADAG) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Adagene currently has a consensus price target of $9.50, indicating a potential upside of 179.41%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 24.89%. Given Adagene's stronger consensus rating and higher probable upside, research analysts plainly believe Adagene is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

9.5% of Adagene shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 21.2% of Adagene shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	29.28	-$17.61M	N/A	N/A
Rigel Pharmaceuticals	$294.28M	2.97	$367.02M	$16.32	2.89

Adagene has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

In the previous week, Adagene had 8 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 10 mentions for Adagene and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.94 beat Adagene's score of 0.31 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 116.30% compared to Adagene's net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Adagene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Summary

Rigel Pharmaceuticals beats Adagene on 9 of the 15 factors compared between the two stocks.

How does Adagene compare to Climb Bio?

Adagene (NASDAQ:ADAG) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Adagene currently has a consensus target price of $9.50, indicating a potential upside of 179.41%. Climb Bio has a consensus target price of $26.92, indicating a potential upside of 88.93%. Given Adagene's higher probable upside, research analysts clearly believe Adagene is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Adagene and Adagene both had 10 articles in the media. Climb Bio's average media sentiment score of 0.90 beat Adagene's score of 0.31 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Climb Bio	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

9.5% of Adagene shares are owned by institutional investors. Comparatively, 69.8% of Climb Bio shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 2.6% of Climb Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adagene's return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Climb Bio	N/A	-31.79%	-30.79%

Adagene has higher revenue and earnings than Climb Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	29.28	-$17.61M	N/A	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Adagene beats Climb Bio on 7 of the 12 factors compared between the two stocks.

How does Adagene compare to Silence Therapeutics?

Adagene (NASDAQ:ADAG) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Adagene currently has a consensus target price of $9.50, suggesting a potential upside of 179.41%. Silence Therapeutics has a consensus target price of $53.50, suggesting a potential upside of 310.91%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

9.5% of Adagene shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Adagene has higher revenue and earnings than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	29.28	-$17.61M	N/A	N/A
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A

Adagene has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

In the previous week, Adagene had 9 more articles in the media than Silence Therapeutics. MarketBeat recorded 10 mentions for Adagene and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.87 beat Adagene's score of 0.31 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Silence Therapeutics	Very Positive

Adagene has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Adagene's return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Summary

Adagene and Silence Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$224.57M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	N/A	14.18	274.94	25.36
Price / Sales	29.28	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	4.53	15.12	10.33	6.20
Net Income	-$17.61M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-5.03%	-4.34%	-3.32%	-2.35%
1 Month Performance	-8.60%	0.54%	-0.53%	-3.23%
1 Year Performance	51.79%	40.74%	23.51%	8.79%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	3.8754 of 5 stars	$3.40 +2.7%	$9.50 +179.4%	+51.8%	$224.57M	$7.67M	N/A	260	News Coverage Analyst Forecast
OLMA Olema Pharmaceuticals	2.6629 of 5 stars	$10.98 +2.1%	$42.40 +286.2%	+31.5%	$940.60M	N/A	N/A	70	News Coverage
ANNX Annexon	2.6169 of 5 stars	$4.67 -4.1%	$15.14 +224.3%	+62.8%	$923.25M	N/A	N/A	60	Positive News
RIGL Rigel Pharmaceuticals	4.4701 of 5 stars	$47.37 -2.7%	$59.00 +24.6%	+24.4%	$900.49M	$276.79M	2.90	160	Analyst Upgrade
CLYM Climb Bio	3.1314 of 5 stars	$15.90 +2.4%	$26.92 +69.3%	+533.3%	$891.41M	N/A	N/A	9	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. OLMA, ANNX, RIGL, CLYM, and SLN

How does Adagene compare to Olema Pharmaceuticals?

Summary

How does Adagene compare to Annexon?

Summary

How does Adagene compare to Rigel Pharmaceuticals?

Summary

How does Adagene compare to Climb Bio?

Summary

How does Adagene compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. OLMA, ANNX, RIGL, CLYM, and SLN

How does Adagene compare to Olema Pharmaceuticals?

Do insiders & institutionals believe in ADAG or OLMA?

Which has more volatility and risk, ADAG or OLMA?

Does the media favor ADAG or OLMA?

Is ADAG or OLMA more profitable?

Which has preferable valuation and earnings, ADAG or OLMA?

Do analysts recommend ADAG or OLMA?

Summary

How does Adagene compare to Annexon?

Do institutionals and insiders believe in ADAG or ANNX?

Does the media favor ADAG or ANNX?

Is ADAG or ANNX more profitable?

Which has higher earnings & valuation, ADAG or ANNX?

Which has more volatility & risk, ADAG or ANNX?

Do analysts rate ADAG or ANNX?

Summary

How does Adagene compare to Rigel Pharmaceuticals?

Do analysts prefer ADAG or RIGL?

Do institutionals & insiders believe in ADAG or RIGL?

Which has higher valuation and earnings, ADAG or RIGL?

Which has more volatility & risk, ADAG or RIGL?

Does the media prefer ADAG or RIGL?

Is ADAG or RIGL more profitable?

Summary

How does Adagene compare to Climb Bio?

Do analysts rate ADAG or CLYM?

Does the media prefer ADAG or CLYM?

Which has more volatility & risk, ADAG or CLYM?

Do institutionals and insiders have more ownership in ADAG or CLYM?

Is ADAG or CLYM more profitable?

Which has preferable earnings & valuation, ADAG or CLYM?

Summary

How does Adagene compare to Silence Therapeutics?

Do analysts prefer ADAG or SLN?

Do insiders & institutionals hold more shares of ADAG or SLN?

Which has stronger earnings and valuation, ADAG or SLN?

Which has more volatility & risk, ADAG or SLN?

Does the media prefer ADAG or SLN?

Is ADAG or SLN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools